On the mechanism of CD47 targeting in cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 42, 2012, Pages

  Zhao, Xi Wen ^a   Matlung, Hanke L ^a   Kuijpers, Taco W ^a   Van Den Berg, Timo K ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; INTEGRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD47; PROTEIN SIRP ALPHA; REGULATOR PROTEIN; RITUXIMAB; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CELL DESTRUCTION; DRUG MECHANISM; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; MACROPHAGE; METASTASIS INHIBITION; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL;

ANTIGENS, CD47; ANTIGENS, DIFFERENTIATION; HUMANS; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER;

EID: 84867656070     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1209265109     Document Type: Letter

References (5)

1. Willingham SB, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109:6662-6667.
2. Han X, et al. (2000) CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem 275:37984-37992. (Pubitemid 32004920)
3. Jiang P, Lagenaur CF, Narayanan V (1999) Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem 274:559-562.
4. Zhao XW, Kuijpers TW, van den Berg TK (2012) Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy? Blood 119:4333-4334, author reply 4334- 4335.
5. Zhao XW, et al. (2011) CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 108:18342-18347.